Sai Parenterals IPO Final Day: NII Demand Lifts Issue to 1.05x Subscription 

Mumbai, March 27: The initial public offering (IPO) of Sai Parenterals Limited concluded its three-day bidding window on Friday with a modest finish, achieving an overall subscription of 1.05 times by the close at 5:00 PM IST. The BSE-bound pharmaceutical player, trading under the symbol SAIPARENT, saw mixed investor participation, with strong interest from non-institutional investors offsetting relatively muted retail demand. 

The issue, comprising 75.22 lakh equity shares within a price band of ₹372–392, attracted cumulative bids for nearly 78.80 lakh shares. Pricing trends suggested measured confidence among investors, with around 78.49 lakh shares bid at the upper end of ₹392, while over 3.5 lakh shares were placed at the cut-off price. The demand pattern indicates cautious participation, with investors selectively backing the issue amid prevailing market conditions. 

Non-Institutional Investors (NIIs) emerged as the key drivers of the IPO, subscribing their allocated portion 2.36 times. Within this segment, the high-net-worth individual category (bids above ₹10 lakh) showed strong traction, oversubscribing 3.43 times, led primarily by individual investors who accounted for over 33.25 lakh shares. Corporate participation remained limited, though it added incremental support to the overall demand. 

Qualified Institutional Buyers (QIBs) also displayed steady interest, subscribing 1.71 times their reserved quota. Demand in this category was led by foreign institutional investors (FIIs), who bid for over 18.50 lakh shares, followed by domestic financial institutions and mutual funds contributing a combined share of over 12.75 lakh shares. This institutional participation provided a stable foundation to the issue. 

In contrast, Retail Individual Investors (RIIs) remained cautious, with the segment subscribed only 0.12 times. Against an allocation of 37.86 lakh shares, bids were received for just 4.39 lakh shares, with a significant portion coming through cut-off applications. The subdued retail response reflects hesitancy among smaller investors, possibly due to valuation concerns or broader market volatility. 

With the IPO now closed, focus shifts to the allotment process, which will be handled by Bigshare Services. The listing performance of Sai Parenterals will be closely monitored, particularly given the strong NII backing but relatively weak participation from retail investors. 

Source: https://www.nseindia.com/market-data/all-upcoming-issues-ipo